Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

Aggregation Tests Identify New Gene Associations With Breast Cancer in Populations With Diverse Ancestry

A Model for Predicting Both Breast Cancer Risk and Non-Breast Cancer Death Among Women Older Than 55 Years Old

GRHL2-Controlled Gene Expression Networks in Luminal Breast Cancer

Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial

High Deductibles Lead Women to Skip Testing After Abnormal Mammogram

Aggrego Pulse - 1/19/23

Breast Cancer Patients From the Midwest Region of the United States Have Reduced Levels of Short-Chain Fatty Acid-Producing Gut Bacteria

Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

header-info

Sep, 19, 2022

Shlomit Amar-Farkash, PhD, MSc, Anthem Innovation Israel, Tel Aviv, Israel compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with metastatic triple-negative breast cancer in the United States.